Key result
Prokinetic therapy during hospitalization for gastroparesis was associated with a longer length of stay (6.7 vs. 3.7 days; p=0.002) and no significant reduction in 30-day readmission rates.
Why the study?
Does prokinetic therapy improve length of stay and 30-day readmission rates in adult patients hospitalized for gastroparesis?
Cohort (n=82)
Does prokinetic therapy improve length of stay and 30-day readmission rates in adult patients hospitalized for gastroparesis?
Absolute Event Rate: 6.7% vs 3.7%
p-value: p=0.002
In patients hospitalized for gastroparesis, prokinetic therapy was not associated with reduced length of stay or 30-day readmission rates, though intravenous administration was associated with shorter stays compared to oral therapy.
Should not change gastroparesis hospitalization practice; leaves open prokinetic efficacy pending randomized trials.
Background/Aim: Hospitalizations due to gastroparesis have increased in the last 20 years with limited advancements in pharmacologic therapy. Although therapy primarily consists of prokinetic agents, little is known about their effects on hospital outcomes. The aim of our study was to determine whether common prokinetic therapies (metoclopramide and erythromycin) improve outcomes in gastroparesis patients.Methods: A retrospective review of adult patients admitted with a primary diagnosis of gastroparesis between 7 January 2011 and 7 January 2014 was conducted. Patients were divided into two groups based on whether they received prokinetic therapy (PRO) during hospitalization or not (NO). Groups were compared to determine length of stay (LOS), 30-day readmission rates, and risk factors affecting these outcomes.Results: Of the 82 patients included in our study, 57 received prokinetic therapy. Mean length of stay (LOS) was 5.8 ± 4.2 days, with a significantly shorter LOS in the NO group (3.7 ± 1.9 vs. 6.7 ± 4.5; p = 0.002). Among patients studied, 30.5% were readmitted within 30 days from discharge with no significant reduction in the PRO group (35.1% PRO vs. 20% NO; p =0.23). Patients with idiopathic gastroparesis had significantly longer LOS (6.9 ± 4.6 vs. 4.2 ± 2.8; p = 0.003). In the PRO group, those who received intravenous (IV) therapy had a significantly shorter LOS (4.9 ± 2.5 IV vs. 8.0 ± 5.3 oral; p = 0.01).Conclusions: Treatment of gastroparesis patients with prokinetic agents did not shorten the LOS nor decrease 30-day readmission rates. In those receiving prokinetics, the IV route was associated with reduced LOS.
No takes yet. Share an insight, caveat, or question.
Roé et al. (2017) conducted a cohort in Gastroparesis (n=82). Prokinetic therapy (metoclopramide and erythromycin) vs. No prokinetic therapy was evaluated on Length of stay (LOS) in days (p=0.002). Prokinetic therapy during hospitalization for gastroparesis was associated with a longer length of stay (6.7 vs. 3.7 days; p=0.002) and no significant reduction in 30-day readmission rates.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: